TD Cowen Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $57
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Joseph Thome maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $55 to $57.
TD Cowen analyst Joseph Thome maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $55 to $57.